Healthcare and pharmaceutical marketing executives, professor Markus Saba and marketer Hilary Gentile, provide a step-by-step formula to uncover the unique needs that drive brand choice in the health and wellness industry.

How can I build my brand when it is just another me-too? is the quintessential question asked by pharma and healthcare marketers operating in the branded generic markets. In highly saturated markets with hundreds of similar brands, establishing a competitive edge and building a strong brand is often a challenging task. The Perfect Pill propagates a robust 10-step healthcare brand-building model that helps you create much-needed differentiation and a unique value proposition for patients and physicians. The steps suggested in the book help establish an ultimate win-win situation for patients, physicians, and sales and marketing professionals. A must-read for pharmaceutical, medical device, diagnostic, over-the-counter, surgical, hospital, nutrition, and wellness brand marketers.

Written by John Lidstone and Janice MacLennan, the second edition of Marketing Planning for the Pharmaceutical Industry became accepted as the bible for the industry. In this new companion book Janice MacLennan picks up two of the themes touched on in Marketing Planning - market segmentation and branding, and the inter-relationship between these two - and with this book makes them key topics for discussion. Brand Planning for the Pharmaceutical Industry begins by exploring what branding is and why it is of importance, particularly to the pharmaceutical sector. The book then goes on to show how branding can be integrated into the early stages of the commercialization process for new products, both in theory and in the 'real' world. The book provides a step-by-step guide to brand planning, using market segmentation as the starting point. The book is split into two parts, the first dealing comprehensively with brand planning for products yet to get to the market, with the second part applying the same process to products that are already on the market. Both parts are extremely pragmatic, full of pertinent examples and insights from the pharmaceutical industry, and are directly applicable to your own brand planning. Brand Planning for the Pharmaceutical Industry concludes by confronting the problems that organizations are likely to have in actually making brand planning an integral part of their work and presents strategies for dealing with them.

The pharma and medtech sectors are evolving rapidly, driven by science, technology, economics, politics and globalization. In the new industry landscape, creating strong brand strategies is ever more difficult and ever more vital. Brand Therapy gives pharma and medtech brand teams the tools to understand their market, create strong strategies and translate them into actionable plans. Written in 16 short, easy chapters, it is essential reading for anyone who works in or with brand teams in the life sciences industry.

Donovan Boyd, "The Marketing Coach," is a passionate, hardworking, attentive business man, and the CEO of The Boyd Group, LLC. Not only does Donovan hold a bachelor's degree in Business Administration with a concentration in Marketing from Fordham University, and an MBA from South University, his professional background consist of 10 years of marketing and brand management experience in education, music, entertainment, and private consulting. Prior to starting The Boyd Group, Donovan served as an intern in the urban marketing department for Atlantic Records and served as a volunteer coordinator for Russell Simmons' Hip Hop Summit Action Network. He spent 2 years as a Marketing Director for a local charter school in Cleveland, OH while maintaining an artist management and promotional company for 4 years. Since then, he created the credible business coaching firm called, The Boyd Group, LLC, with the mission to help businesses & individuals unlock their brand potential through innovative strategies that create brand value & aid customer loyalty. Donovan's passion is to travel the country and educate people on the growth opportunities within their business. His latest book, The Brand Playbook, is the precise tool needed for new and future entrepreneurs. Through Donovan's varied background, he has set the perfect foundation for effective branding and marketing as "The Marketing Coach."

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.